<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OALibJ</journal-id><journal-title-group><journal-title>Open Access Library Journal</journal-title></journal-title-group><issn pub-type="epub">2333-9705</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/oalib.1102603</article-id><article-id pub-id-type="publisher-id">OALibJ-69198</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject><subject> Business&amp;Economics</subject><subject> Chemistry&amp;Materials Science</subject><subject> Computer Science&amp;Communications</subject><subject> Earth&amp;Environmental Sciences</subject><subject> Engineering</subject><subject> Medicine&amp;Healthcare</subject><subject> Physics&amp;Mathematics</subject><subject> Social Sciences&amp;Humanities</subject></subj-group></article-categories><title-group><article-title>
 
 
  On Analysis of Parameter Estimation Model for the Treatment of Pathogen-Induced HIV Infectivity
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bassey</surname><given-names>E. Bassey</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lebedev</surname><given-names>K. Andreyevich</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Department of Computational Mathematics and Informatics, Kuban State University, Krasnodar, Russia</addr-line></aff><aff id="aff1"><addr-line>Department of Mathematical and Computer Methods, Kuban State University, Krasnodar, Russia</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>awaserex@ymail.com(BEB)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>04</month><year>2016</year></pub-date><volume>03</volume><issue>04</issue><fpage>1</fpage><lpage>13</lpage><history><date date-type="received"><day>3</day>	<month>April</month>	<year>2016</year></date><date date-type="rev-recd"><day>accepted</day>	<month>18</month>	<year>April</year>	</date><date date-type="accepted"><day>22</day>	<month>April</month>	<year>2016</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   Multiplicity of new cases of HIV/AIDS and its allied infectious diseases daunted by lack of proper parametric estimation necessitated this present work. Formulated using ordinary differential equation was a five-dimensional (5D) differential mathematical model with which compatibility of optimal control strategy for dual (viral load and parasitoid-pathogen) infectivity in the blood plasma was investigated. Discretization method indicated the incompatibility of the model due to large error derivatives. The study using numerical method established treatment set point with which we explored the variation of predominant model parameters and thereof investigated the maximization of uninfected healthy CD4
   <sup style="line-height:1.5;"> </sup>
    T cell count as well as the de-replication of viruses following the consistent administration of reverse transcriptase inhibitor from set point. Presented was a series of numerical calculations obtained using well-known Runge-Kutter of order of precision 4, in Mathcad platform. Analysis of simulated parameters showed that distortion of replication viruses and de-transmutation of susceptible CD4
   <sup style="line-height:1.5;"> </sup>
    T cells by viruses via chemotherapy led to restoration and gradual increase of healthy blood plasma, with near zero declination of both viral load and parasitoid-pathogen within chemotherapy validity time frame. The model was worthy in the study of treatment analysis of dual HIV—pathogen infection and thereof recommended for other related dual infectious diseases. 
  
 
</p></abstract><kwd-group><kwd>Asymptomatic-Stage</kwd><kwd> De-Replication</kwd><kwd> Discretization</kwd><kwd> Infectivity</kwd><kwd> Mutation-Ability</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Still a daunting hurdle for the scientists of infectious diseases is the unfounded clear medical literature for the absolute eradication of the human immune deficiency virus (HIV), a primary route of the dreaded disease called Acquired Immune Deficiency Syndrome (AIDS). In the circumstance, suppression and prevention of HI-virus and its associated infectious diseases have become an inevitable remedy in the annals of study into the cure for HIV/AIDS. Further hindrance to the achievable goals from both clinical trials and scientific researches is the multiplicity of new cases of HIV/AIDS and its affiliated infectious diseases.</p><p>The formulation and analysis of HI-virus and its allies significantly revolve round the parameters with which the models are formulated. Therefore, evaluation (or estimation) of the parameters is of paramount importance. Attempts in this direction by a number of researchers [<xref ref-type="bibr" rid="scirp.69198-ref1">1</xref>] - [<xref ref-type="bibr" rid="scirp.69198-ref6">6</xref>] include the use of 3-Dimensional (3D)―Ordinary Differential Equations (ODEs), with most models presented as optimal control problems. Visible constraints from outcomes of these works have been the indistinguishable nature of the infected CD4<sup>+</sup> T cells from the uninfected CD4<sup>+</sup> T cells [<xref ref-type="bibr" rid="scirp.69198-ref7">7</xref>] .</p><p>In this present paper, we presuppose two infectious parasitoid-pathogenic induced HIV infections. The study is formulated as a 5-Dimensional (5D)―ODE model aimed at investigating the compatibility of optimal control strategy for the treatment of HIV and its allies of infections. Use as treatment factor is reverse transcriptase inhibitor (RTI) with the blood plasma (CD4<sup>+</sup> T cells) as the prime host. Unlike several other studies conducted using 3-Dimensional differential equations, on a single HIV infection, the novelty of this present paper lies in the enhance formulation of 5-Dimensional mathematical model, propose to investigate the parameter estimation of dual HIV―pathogen induced infection. Thus, the objective is in the investigation of the compatibility of optimal control strategy for the estimation of model parameters of dual HIV―pathogen infection. Therefore, the present work does not only accounts to establish the compatibility of application of optimal control in parameter estimation of dual infectious diseases but also, accounts for viral load de-replication and de-transmutation of pathogen resistivity through varying of model parameters. The model explores numerical method via discretization techniques (method), with numerical illustrations using Range-Kutter of order of precision 4, in Mathcad platform.</p><p>Exceptional works on parameter estimations include: virus clearance rate and death rates of infected CD4<sup>+</sup> T cells [<xref ref-type="bibr" rid="scirp.69198-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.69198-ref3">3</xref>] ; the analysis based on the quasi-steady state of the asymptomatic period before it is disturbed by chemotherapy [<xref ref-type="bibr" rid="scirp.69198-ref8">8</xref>] . The model [<xref ref-type="bibr" rid="scirp.69198-ref1">1</xref>] investigated the optimal control strategy for a full determined HIV model aimed at clinical testing and monitoring of HIV/AIDS diseases. In that study, demonstrated was the CD4<sup>+</sup> T cells measurement and viral load count, using reverse transcriptase inhibitor (RTI) as single treatment. Other notable models involving discretization methods for parameter estimations could be found in [<xref ref-type="bibr" rid="scirp.69198-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.69198-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.69198-ref10">10</xref>] . The deployment of highly antiretroviral therapy (HAART) regimen in the treatment and suppression of viral replication and immune system recovery were studied by [<xref ref-type="bibr" rid="scirp.69198-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.69198-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.69198-ref12">12</xref>] . The study [<xref ref-type="bibr" rid="scirp.69198-ref13">13</xref>] had discussed on the impact of numerical stability of the treatment of vertical transmitted HIV/AIDS infections; while global convergence and impact of multistage and Pad&#233; techniques for iterative chain model were contained in [<xref ref-type="bibr" rid="scirp.69198-ref14">14</xref>] .</p><p>The scope of this work is characterized by four subsections, which includes: introductory aspect as in Section 1. The material and methods of the model, which includes: System modalities as a problem statement, discretization technique and model parameter variation constitute Section 2. Section 3 is covered by a number of numerical illustrations and discussion, while the last Section 4 is devoted to conclusion and recommended remarks. The study is anticipated to throw more insight to compatibility of optimal control strategy in 5D-model in the treatment of dual infectivity.</p></sec><sec id="s2"><title>2. Material and Methods</title><p>We present in this section, the statement of the problem and model formulation followed by the discretization technique used, as well as model parameter variation of the system.</p><sec id="s2_1"><title>2.1. Problem Statement and Model Formulation</title><p>In our presupposition to study the compatibility of optimal control strategy for the treatment of dual HIV―pa- thogen induced infection; we bring to relation, ordinary differential equation in mathematical modeling, structured as problem statement solvable possibly by discretization method.</p><p>We construct our model from a considered population density consisting of five different subpopulations, giving rise to a set of five ordinary differential equations captured from the pictorial representation of <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p><p>Physiologically, we let <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x7.png" xlink:type="simple"/></inline-formula> denote the uninfected CD4<sup>+</sup> T cells, <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x8.png" xlink:type="simple"/></inline-formula>-HIV virus (viral load), <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x9.png" xlink:type="simple"/></inline-formula>-parasitoid- pathogen; then for virus-infected CD4<sup>+</sup> T cells and pathogen-infected CD4<sup>+</sup> T cells, we shall denote by <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x10.png" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x11.png" xlink:type="simple"/></inline-formula> respectively. The biological description of the parameters with which these variables interact and its corresponding ODE’s are defined as in <xref ref-type="table" rid="table1">Table 1</xref>, thereof:</p><p>The differential equation of the model is derived as follows:</p><disp-formula id="scirp.69198-formula1203"><label>(2.1)</label><graphic position="anchor" xlink:href="http://html.scirp.org/file/69198x12.png"  xlink:type="simple"/></disp-formula><p>and satisfying all the variables and parameters as defined in <xref ref-type="table" rid="table2">Table 2</xref>.</p><p>Biologically, Equations (2.1) assumed a relatively steady viral level during the asymptomatic stage of HIV and pathogen infection known as “set-point”. At this initial set-point, the body develops an immune system called, the innate immune system, which act as antibodies against HIV-infection and pathogen barrier preventing mechanism. However, the replication of viral load and the rapid adaptivity of pathogen make it impossible for easy detection and subsequently neutralize this innate immune system, which then leads to gradual full blown AIDS [<xref ref-type="bibr" rid="scirp.69198-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.69198-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.69198-ref16">16</xref>] . It is known that for most HIV patients, <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x13.png" xlink:type="simple"/></inline-formula>and<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x14.png" xlink:type="simple"/></inline-formula>, which also holds for <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x15.png" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x16.png" xlink:type="simple"/></inline-formula> [<xref ref-type="bibr" rid="scirp.69198-ref4">4</xref>] .</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Biological description of HIV―pathogenic infection model</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Biological description</th><th align="center" valign="middle" >Interaction</th><th align="center" valign="middle" >Reaction rate</th><th align="center" valign="middle" >Translation to ODE</th></tr></thead><tr><td align="center" valign="middle" >CD4<sup>+</sup> T cells production.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x17.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x18.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x19.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" >CD4<sup>+</sup> T cells natural death.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x20.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x21.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x22.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" >CD4<sup>+</sup> T cells become infected by virus. Rate at which virus attack CD4<sup>+</sup> T cells.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x23.png" xlink:type="simple"/></inline-formula> <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x24.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x25.png" xlink:type="simple"/></inline-formula> <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x26.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x27.png" xlink:type="simple"/></inline-formula> <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x28.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" >CD4<sup>+</sup> T cells invaded by pathogen. Rate at which pathogen invade CD4<sup>+</sup> T cells.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x29.png" xlink:type="simple"/></inline-formula> <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x30.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x31.png" xlink:type="simple"/></inline-formula> <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x32.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x33.png" xlink:type="simple"/></inline-formula> <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x34.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" >Death of virus infected CD4<sup>+</sup> T cells.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x35.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x36.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x37.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" >Virus replication in infected CD4<sup>+</sup> T cells.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x38.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x39.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x40.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" >Virus natural death.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x41.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x42.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x43.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" >Death of pathogen infected CD4<sup>+</sup> T cells.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x44.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x45.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x46.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" >Pathogen replication in infected CD4<sup>+</sup> T cells.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x47.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x48.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x49.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" >Elimination of pathogens.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x50.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x51.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x52.png" xlink:type="simple"/></inline-formula></td></tr></tbody></table></table-wrap><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Pictorial representation of HIV―pathogenic infection model</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/69198x53.png"/></fig><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Variables and parameters values of optimal control for model (2.1)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Dependent variables</th><th align="center" valign="middle" >Initial values</th></tr></thead><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x54.png" xlink:type="simple"/></inline-formula>Uninfected CD4<sup>+</sup> T cells population. <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x55.png" xlink:type="simple"/></inline-formula>Viral load infected CD4<sup>+</sup> T cells. <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x56.png" xlink:type="simple"/></inline-formula>Parasitoid-pathogen infected CD4+ T cells.</td><td align="center" valign="middle" >0.8/mm<sup>3</sup> 0.01/mm<sup>3</sup> 0.01/mm<sup>3</sup></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x57.png" xlink:type="simple"/></inline-formula>HIV (viral load) population.</td><td align="center" valign="middle" >0.08/ml</td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x58.png" xlink:type="simple"/></inline-formula>Parasitoid-pathogen.</td><td align="center" valign="middle" >0.07/ml</td></tr><tr><td align="center" valign="middle" >Parameters and Constants</td><td align="center" valign="middle" >Values</td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x59.png" xlink:type="simple"/></inline-formula>CD4<sup>+</sup> T cells natural source production.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x60.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x61.png" xlink:type="simple"/></inline-formula>Natural death rate of uninfected CD4<sup>+</sup> T cells.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x62.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x63.png" xlink:type="simple"/></inline-formula>Death rate of HI-virus infected CD4<sup>+</sup> T cells.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x64.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x65.png" xlink:type="simple"/></inline-formula>Death rate of P-pathogen infected CD4<sup>+</sup> T cells.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x66.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x67.png" xlink:type="simple"/></inline-formula>HI-virus replication in infected cells.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x68.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x69.png" xlink:type="simple"/></inline-formula>P-pathogen replication in infected cells.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x70.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x71.png" xlink:type="simple"/></inline-formula>HI-virus natural death rate.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x72.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x73.png" xlink:type="simple"/></inline-formula>Elimination (clearance) rate of P-pathogen.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x74.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x75.png" xlink:type="simple"/></inline-formula>Rate of CD4+ T cells infection by HI-virus.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x76.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x77.png" xlink:type="simple"/></inline-formula>Rate of CD4+ T cells infection by P-pathogen.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x78.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x79.png" xlink:type="simple"/></inline-formula>CD4<sup>+</sup> T cells invaded by pathogen.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x80.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x81.png" xlink:type="simple"/></inline-formula>CD4<sup>+</sup> T cells become infected by virus.</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x82.png" xlink:type="simple"/></inline-formula></td></tr></tbody></table></table-wrap><p>Furthermore, it can be shown mathematically from Equation (2.1), that the amount of <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x83.png" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x84.png" xlink:type="simple"/></inline-formula> in the set-point are given by the equilibrium of virus and parasitoid-pathogen depicted</p><p>i.e.</p><disp-formula id="scirp.69198-formula1204"><label>(2.2)</label><graphic position="anchor" xlink:href="http://html.scirp.org/file/69198x85.png"  xlink:type="simple"/></disp-formula><p>Thus, model (2.1) adequately reflected the disease progression from initial infection to an asymptomatic stage [<xref ref-type="bibr" rid="scirp.69198-ref5">5</xref>] .</p></sec><sec id="s2_2"><title>2.2. Discretization Technique</title><p>The discretization method which is aimed at estimating all the parameters of HIV and pathogen as involved in our basic model (2.1) is applied here. The method affords us the opportunity to transform and study the compatibility of equations as in model (2.1) into solvable discrete form. Clearly, with discretization method, we aim to estimate (or measure) all the twelve parameters in model (2.1). None-the-less, we shall deliberately omit the va-</p><p>riables <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x86.png" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x86.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x87.png" xlink:type="simple"/></inline-formula> at the set-point (initial stage) of our parameter estimation in view of the following limitations:</p><p>1) The microscopically indistinguishable nature of infected cells from the uninfected cells which leads to development of state estimator is a factor [<xref ref-type="bibr" rid="scirp.69198-ref7">7</xref>] .</p><p>2) Extreme high cost of quantification of these infected cells at the set-point is another factor [<xref ref-type="bibr" rid="scirp.69198-ref1">1</xref>] .</p><p>3) The number of infected CD4<sup>+</sup> T cells at the set-point is found to be too small (negligible) compared to the number of healthy CD4<sup>+</sup> T cells [<xref ref-type="bibr" rid="scirp.69198-ref4">4</xref>] .</p><p>4) At the set-point, treatments are certainly not administered from the first hour/day or even weeks of initial infection. Therefore, estimation of parameters starts with setting <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x88.png" xlink:type="simple"/></inline-formula> and<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x88.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x89.png" xlink:type="simple"/></inline-formula>, to be able to obtain desired interval for drugs administration.</p><p>Therefore, we see from Equation (2.1) that the first and second derivatives becomes</p><disp-formula id="scirp.69198-formula1205"><label>(2.3)</label><graphic position="anchor" xlink:href="http://html.scirp.org/file/69198x90.png"  xlink:type="simple"/></disp-formula><p>which is the equation representing the progression of infection at the asymptomatic stage.</p><p>Equations (2.3) accounts for the model parameters without <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x91.png" xlink:type="simple"/></inline-formula> and<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x91.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x92.png" xlink:type="simple"/></inline-formula>. Biologically, these clearly indicate that infection of CD4<sup>+</sup> T cells by viral load and parasitoid pathogen (<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x91.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x92.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x93.png" xlink:type="simple"/></inline-formula>and<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x91.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x92.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x93.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x94.png" xlink:type="simple"/></inline-formula>) at set point through asymptomatic stage are indistinguishable from healthy CD4<sup>+</sup> T cells and are insignificant. Hence, the death rates (<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x91.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x92.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x93.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x94.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x95.png" xlink:type="simple"/></inline-formula>and<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x91.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x92.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x93.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x94.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x95.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x96.png" xlink:type="simple"/></inline-formula>) of these viruses at set point and in the short period after chemotherapy treatment of the CD4<sup>+</sup> T-cell count does not change significantly (see assumptions i, iii &amp; iv). Therefore, the conditions <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x91.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x92.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x93.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x94.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x95.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x96.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x97.png" xlink:type="simple"/></inline-formula> and<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x91.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x92.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x93.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x94.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x95.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x96.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x97.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x98.png" xlink:type="simple"/></inline-formula>, given above is justified, [<xref ref-type="bibr" rid="scirp.69198-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.69198-ref5">5</xref>] . Surpassing the asymptomatic stage (or at symptomatic stage/chronic level) with<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x91.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x92.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x93.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x94.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x95.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x96.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x97.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x98.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x99.png" xlink:type="simple"/></inline-formula>, Equation (2.1), using Equation (2.3), becomes:</p><disp-formula id="scirp.69198-formula1206"><label>(2.4)</label><graphic position="anchor" xlink:href="http://html.scirp.org/file/69198x100.png"  xlink:type="simple"/></disp-formula><p>Equation (2.4) is a nonlinear optimal control problem (NOCP), with uncertain parameters, which necessarily need to be transform into a new problem in the form of calculus of variations from which we can apply nonlinear programming (NLP) approach. This step is obvious in order to simplify the seemingly complex biological equations (containing many variables and model parameters) into a few numbers of indicators without loss of originality.</p><p>Achieving this, we rewrite Equation (2.4) by introducing new variables i.e. let<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x101.png" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x101.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x102.png" xlink:type="simple"/></inline-formula>and<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x101.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x102.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x103.png" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x101.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x102.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x103.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x104.png" xlink:type="simple"/></inline-formula>and such that the twelve parameters in model (2.1) are denoted by the coefficients<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x101.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x102.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x103.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x104.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x105.png" xlink:type="simple"/></inline-formula>. Then we have,</p><disp-formula id="scirp.69198-formula1207"><label>(2.5)</label><graphic position="anchor" xlink:href="http://html.scirp.org/file/69198x106.png"  xlink:type="simple"/></disp-formula><p>This is to say that the coefficients of the original system can be expressed through the new coefficients as follows:</p><disp-formula id="scirp.69198-formula1208"><graphic  xlink:href="http://html.scirp.org/file/69198x107.png"  xlink:type="simple"/></disp-formula><p>Therefore, by discretization of Equation (2.5) and substitution of approximate values of the first derivative of<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x108.png" xlink:type="simple"/></inline-formula>, for CD4<sup>+ </sup>T cells; the first and second derivatives of <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x108.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x109.png" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x108.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x109.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x110.png" xlink:type="simple"/></inline-formula> for viral load and pathogen; as well as the first derivative of <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x108.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x109.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x110.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x111.png" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x108.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x109.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x110.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x111.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x112.png" xlink:type="simple"/></inline-formula> for infected CD4<sup>+</sup> T cells by viruses respectively, we can investigate the measurement of the variables at different time intervals. That is, having the experimental dependence of<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x108.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x109.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x110.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x111.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x112.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x113.png" xlink:type="simple"/></inline-formula>, Equation (2.5) can be written as the system of algebraic equations relative to the vector<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x108.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x109.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x110.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x111.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x112.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x113.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x114.png" xlink:type="simple"/></inline-formula>, i.e.</p><disp-formula id="scirp.69198-formula1209"><label>(2.6)</label><graphic position="anchor" xlink:href="http://html.scirp.org/file/69198x115.png"  xlink:type="simple"/></disp-formula><p>Similarly, for a <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x116.png" xlink:type="simple"/></inline-formula> matrices, we have</p><p><img data-original="http://html.scirp.org/file/69198x117.png" />,<img data-original="http://html.scirp.org/file/69198x118.png" /> (2.7)</p><p><img data-original="http://html.scirp.org/file/69198x119.png" />,<img data-original="http://html.scirp.org/file/69198x120.png" /> (2.8)</p><p>In matrix form, taking Equation (2.6), we have,</p><disp-formula id="scirp.69198-formula1210"><label>(2.9)</label><graphic position="anchor" xlink:href="http://html.scirp.org/file/69198x121.png"  xlink:type="simple"/></disp-formula><p>Matricizing Equations (2.7), we derive as follows:</p><disp-formula id="scirp.69198-formula1211"><label>(2.10)</label><graphic position="anchor" xlink:href="http://html.scirp.org/file/69198x122.png"  xlink:type="simple"/></disp-formula><p>Similarly, for Equation (2.8), we have,</p><disp-formula id="scirp.69198-formula1212"><label>(2.11)</label><graphic position="anchor" xlink:href="http://html.scirp.org/file/69198x123.png"  xlink:type="simple"/></disp-formula><p>Therefore, the basic model (2.5) which has been transformed to the matrix equations (2.9)-(2.11), satisfies the vector properties and each can be written as a vector form</p><disp-formula id="scirp.69198-formula1213"><label>(2.12)</label><graphic position="anchor" xlink:href="http://html.scirp.org/file/69198x124.png"  xlink:type="simple"/></disp-formula><p>Equation (2.12), justify that our model is described by quantifiable magnitude and has direction of purpose. Furthermore, it is observed that Equation (2.5) contains twelve unknown parameters, i.e. the variables<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x125.png" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x125.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x126.png" xlink:type="simple"/></inline-formula>, with which all the parameters of the basic model (2.1) can be calculated. A case study of some of the parameter estimation as in basic model (2.1) can be found in [<xref ref-type="bibr" rid="scirp.69198-ref4">4</xref>] . Therefore, to determine these parameters, it becomes necessary to generate a minimum of 12 equations based on Equation (2.5). This can be achieved by differentiating Equation (2.5), more times, resulting in derivatives of <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x125.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x126.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x127.png" xlink:type="simple"/></inline-formula> and<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x125.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x126.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x127.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x128.png" xlink:type="simple"/></inline-formula>, up to the order of measurement . In coping with these orders of derivatives, we need at least</p><p><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x129.png" xlink:type="simple"/></inline-formula>and<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x129.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x130.png" xlink:type="simple"/></inline-formula>,</p><p>(where the superscripts denote sample numbers) measurements for the complete determination of all the HIV/AIDS parameters in the five-dimensional model (2.1), [<xref ref-type="bibr" rid="scirp.69198-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.69198-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.69198-ref5">5</xref>] .</p><p>Then, from Equation (2.5), the identifiability of<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x131.png" xlink:type="simple"/></inline-formula>, means that all the parameters of our model (2.1) can be determined from the output of the CD4<sup>+</sup> T cell count, viral load, parasitoid pathogen, HI-virus infected CD4<sup>+</sup> T cells and pathogen infected CD4<sup>+</sup> T cells. Thus, we establish (as in <xref ref-type="table" rid="table3">Table 3</xref>) below, the available measurement for the count of CD4<sup>+</sup> T cells, viral load and pathogens, HI-virus infected CD4<sup>+</sup> T cells and pathogen infected CD4<sup>+</sup> T cells at varying time intervals:</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Obtained values for parameters of basic model (2.1)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Time (t)</th><th align="center" valign="middle" >CD4<sup>+</sup> T cell count (y<sub>1</sub>)</th><th align="center" valign="middle" >Viral load (y<sub>2</sub>)</th><th align="center" valign="middle" >Pathogen (y<sub>3</sub>)</th><th align="center" valign="middle" >Infected CD4<sup>+</sup> T cell by HIV (y<sub>4</sub>)</th><th align="center" valign="middle" >Infected CD4<sup>+</sup> T cell by HIV (y<sub>5</sub>)</th></tr></thead><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x132.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x133.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x134.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x135.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x136.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x137.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x138.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x139.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x140.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x141.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x142.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x143.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x144.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x145.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x146.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x147.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x148.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x149.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x150.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x151.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x152.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x153.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x154.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x155.png" xlink:type="simple"/></inline-formula></td></tr><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x156.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x157.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x158.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x159.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x160.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x161.png" xlink:type="simple"/></inline-formula></td></tr></tbody></table></table-wrap><p>Then using a number of these measurements, we investigate if the matrix A, of Equation (2.12) is nonsingular (not equal to zero); a condition for unique solution for the coefficients <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x162.png" xlink:type="simple"/></inline-formula> and hence, a prime modality for estimation of the model parameters <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x162.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x163.png" xlink:type="simple"/></inline-formula> Furthermore, this investiga-</p><p>tion is prompted by the fact that, at long asymptomatic stage (set point) and at the short period after administration of chemotherapy, when either of the<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x164.png" xlink:type="simple"/></inline-formula>, is constant, the matrix A, can never be nonsingular for any choice of number of measurements. Therefore, a complete determination of the model parameters is imperatively impossible due to these two periods of time [<xref ref-type="bibr" rid="scirp.69198-ref5">5</xref>] . To compute the values for the parameters <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x164.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x165.png" xlink:type="simple"/></inline-formula> of our model system, we need to compute each of the determinants of Equations (2.9)-(2.11). We see that the determinants of Equations (2.9)-(2.11) are not equal to zero, but very small, in the range of <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x164.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x165.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x166.png" xlink:type="simple"/></inline-formula> Therefore, applying Equation (2.12), that is, we need from Equation (2.12), <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x164.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x165.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x166.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x167.png" xlink:type="simple"/></inline-formula>to solve Equations (2.9)-(2.11), for the parameters<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x164.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x165.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x166.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x167.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x168.png" xlink:type="simple"/></inline-formula>. The following results were obtain</p><disp-formula id="scirp.69198-formula1214"><graphic  xlink:href="http://html.scirp.org/file/69198x169.png"  xlink:type="simple"/></disp-formula><p>Here, the solution, <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x170.png" xlink:type="simple"/></inline-formula>, implies</p><p><img data-original="http://html.scirp.org/file/69198x173.png" /><img data-original="http://html.scirp.org/file/69198x172.png" /><img data-original="http://html.scirp.org/file/69198x171.png" /></p><p>So we see that as a result of the significantly small determinant, the computation of the coefficients<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x174.png" xlink:type="simple"/></inline-formula>, all yields large error derivative when compared with the parameter values of our optimal control as in <xref ref-type="table" rid="table2">Table 2</xref>, above. Whence, compatibility of optimal control strategy via discretization for a 5-D mathematical model is seemingly elusive. Non-the-less, other possible options include:</p><p>a) Application of derived formula for high order of accuracy;</p><p>b) Carrying out interpolation followed by computation of the derivative of the interpolating polynomials;</p><p>c) Since the regions of the coefficients are all non-negative, we account for the estimation of the model parameters by stepwise variation of the parameter values in order to study their respective behavior to viral load replication and pathogen resistivity.</p><p>In general, for options (a) and (b), we need small time interval range of 3 - 4 years and require calculating the derivative in the middle of the steps, resulting to complex procedures. In this case, patients are likely to die without waiting for simulation results. Therefore, option (c), is convenient for the estimation of model parameters. Thus by option (c), we return to Equation (2.1), from which we define the coefficients of our set-point. This criteria is of essence for the simple fact that, it a process to overcome indistinguishability nature of the infected cells and the uninfected cells immediately after asymptomatic stage. It also aid in the definition of treatment time limits and as an overall check to our earlier assumptions. Furthermore, chemotherapy has a certain designated time for allowable treatment, since HIV is able to build up resistance after finite time frame due to its mutation ability and its potential hazardous side effects [<xref ref-type="bibr" rid="scirp.69198-ref17">17</xref>] .</p><p>Keeping the parameters values of <xref ref-type="table" rid="table2">Table 2</xref> in view, we determine the solution of the model (2.1) for the set-point, with the initial values of the coefficients generated as:<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x175.png" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x175.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x176.png" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x175.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x176.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x177.png" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x175.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x176.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x177.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x178.png" xlink:type="simple"/></inline-formula>,<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x175.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x176.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x177.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x178.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x179.png" xlink:type="simple"/></inline-formula> , using well-known numerical method like RK4 in a Mathcad environment, we presents the graphical simulations as in Figures 2 (a)-(e).</p><p>Figures 2(a)-(e) shows decrease in the numbers of susceptible CD4<sup>+</sup> T cells. That is, at<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x180.png" xlink:type="simple"/></inline-formula>, is the minimum count of CD4<sup>+</sup> T cells. So, the treatment interval is <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x180.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x181.png" xlink:type="simple"/></inline-formula> months, [<xref ref-type="bibr" rid="scirp.69198-ref18">18</xref>] - [<xref ref-type="bibr" rid="scirp.69198-ref20">20</xref>] . This is evident by</p><fig-group id="fig2"><label><xref ref-type="fig" rid="fig2">Figure 2</xref></label><caption><title> Graphical simulation of basic model (2.1) at set-point without treatment. (a) Simulation of uninfected CD4+ T cells for<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x185.png" xlink:type="simple"/></inline-formula>; (b) Simulation of HI-virus infected CD4<sup>+</sup> T cells for<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x185.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x186.png" xlink:type="simple"/></inline-formula>; (c) Simulation of pathogen infected CD4+ T cells for<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x185.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x186.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x187.png" xlink:type="simple"/></inline-formula>; (d) Simulation of viral load in the blood plasma for<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x185.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x186.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x187.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x188.png" xlink:type="simple"/></inline-formula>; Simulation of pathogen in the blood plasma for<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x185.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x186.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x187.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x188.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x189.png" xlink:type="simple"/></inline-formula>.</title></caption><fig id ="fig2_1"><label> (b)</label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/69198x182.png"/></fig><fig id ="fig2_2"><label>(c)</label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/69198x183.png"/></fig><fig id ="fig2_3"><label> (d)</label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/69198x184.png"/></fig></fig-group><p>the initial sharp inclination of HI-virus infected CD4<sup>+</sup> T cells (i.e.<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x190.png" xlink:type="simple"/></inline-formula>) and pathogenic-infected</p><p>CD4<sup>+</sup> T cells (i.e.<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x191.png" xlink:type="simple"/></inline-formula>) and then experience steady decline in population due to the influence of the viruses. Also observed, are the decrease in the numbers of free viruses which has become replicated in the blood plasma (CD4<sup>+</sup> T cells), as indicated by <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x191.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x192.png" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x191.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x192.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x193.png" xlink:type="simple"/></inline-formula> respectively. This gives a lead way in our investigation following the initiation of chemotherapy.</p></sec></sec><sec id="s3"><title>3. Numerical Illustrations and Discussion</title><p>Here, the decision for RTI as the chemotherapy follows its dual characteristics tailored on viral load and the activation of the adaptive immune system, which act against parasitoid-pathogen. Specifically, RTI is responsible for the prevention of uninfected lymphocyte cells from infection by viral load and as well, the elimination of infected pathogen cells [<xref ref-type="bibr" rid="scirp.69198-ref18">18</xref>] . Consistent and cogent application of RTI by HIV infected patients insulate replication of viruses (i.e. direct reduction in model parameters, k and d). In the exact circumstance, CD4<sup>+ </sup>T cells becoming infected by viruses diminish in rate (i.e. decrease in <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x194.png" xlink:type="simple"/></inline-formula> and<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x194.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x195.png" xlink:type="simple"/></inline-formula>). Therefore, the behaviors of these parameters afford the desired investigation of the model parameters, which predicts the outcome of the healthy CD4<sup>+</sup> T cells.</p><p>Illustratively, keeping in view other parameter values as in <xref ref-type="table" rid="table2">Table 2</xref>, together with the outcome of <xref ref-type="fig" rid="fig2">Figure 2</xref> (set point values) above, we investigate the treatment for which <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x196.png" xlink:type="simple"/></inline-formula> and<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x196.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x197.png" xlink:type="simple"/></inline-formula>, the simulation of which are presented in Figures 3(a)-(e).</p><p>We see from Figures 3(a)-(e), that with intensive commencement of chemotherapy for <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x198.png" xlink:type="simple"/></inline-formula> months, when <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x198.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x199.png" xlink:type="simple"/></inline-formula> and<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x198.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x199.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x200.png" xlink:type="simple"/></inline-formula>;<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x198.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x199.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x200.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x201.png" xlink:type="simple"/></inline-formula>, increases sharply to <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x198.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x199.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x200.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x201.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x202.png" xlink:type="simple"/></inline-formula> in <xref ref-type="fig" rid="fig3">Figure 3</xref>(a). This in-</p><fig id="fig3"  position="float"><label><xref ref-type="fig" rid="fig3">Figure 3</xref></label><caption><title> (a)-(e): Simulation of model (2.1); at initiation of chemotherapy for <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x204.png" xlink:type="simple"/></inline-formula> and<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x204.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x205.png" xlink:type="simple"/></inline-formula>. (a) Simulation of uninfected CD4<sup>+</sup> T cells for<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x204.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x205.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x206.png" xlink:type="simple"/></inline-formula>; (b) Simulation of HI-virus infected CD4<sup>+</sup> T cells for<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x204.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x205.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x206.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x207.png" xlink:type="simple"/></inline-formula>; (c) Simulation of pathogen infected CD4<sup>+</sup> T cells for<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x204.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x205.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x206.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x207.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x208.png" xlink:type="simple"/></inline-formula>; (d) Simulation of viral load in the blood plasma for<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x204.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x205.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x206.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x207.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x208.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x209.png" xlink:type="simple"/></inline-formula>; (e) Simulation of pathogen in the blood plasma for<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x204.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x205.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x206.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x207.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x208.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x209.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x210.png" xlink:type="simple"/></inline-formula></title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/69198x203.png"/></fig><p>crease in healthy CD4<sup>+</sup> T cells is evident by the drastic decline in the rate of HI-virus infected CD4<sup>+</sup> T cells from <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x211.png" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x211.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x212.png" xlink:type="simple"/></inline-formula> in <xref ref-type="fig" rid="fig3">Figure 3</xref>(b) and parasitoid-pathogen infected CD4<sup>+</sup> T cells from</p><p><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x213.png" xlink:type="simple"/></inline-formula>to near zero after 14 months in <xref ref-type="fig" rid="fig3">Figure 3</xref>(c). Also, we observe that the de-replication progress of infected CD4<sup>+</sup> T cells, adversely attribute to sharp decline (suppression) of viral load in blood plasma from <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x213.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x214.png" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x213.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x214.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x215.png" xlink:type="simple"/></inline-formula> in <xref ref-type="fig" rid="fig3">Figure 3</xref>(d). Pathogen parasite is seen eliminated to near zero after 11 months of drug application in <xref ref-type="fig" rid="fig3">Figure 3</xref>(e).</p><p>Furthermore, observing the same model coefficients as in Figures 3(a)-(e), but with reduced rate of CD4<sup>+</sup> T cells becoming infected by both viral load and pathogen, following adherent administration of chemotherapy (i.e. <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x216.png" xlink:type="simple"/></inline-formula>and<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x216.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x217.png" xlink:type="simple"/></inline-formula>), the simulated results are as presented in Figures 4(a)-(e).</p><p>Analysis from <xref ref-type="fig" rid="fig4">Figure 4</xref>(a) shows that a more enhanced outcome for healthy CD4<sup>+</sup> T cells was experience at <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x218.png" xlink:type="simple"/></inline-formula> with constant inflow of <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x218.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x219.png" xlink:type="simple"/></inline-formula> and accompanied by tremendous decline of both infected HI-virus CD4<sup>+</sup> T cells and parasitoid-pathogen infected CD4<sup>+</sup> T cells. <xref ref-type="fig" rid="fig4">Figure 4</xref>(b), showed decline of <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x218.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x219.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x220.png" xlink:type="simple"/></inline-formula> from <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x218.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x219.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x220.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x221.png" xlink:type="simple"/></inline-formula></p><fig id="fig4"  position="float"><label><xref ref-type="fig" rid="fig4">Figure 4</xref></label><caption><title> (a)-(e): Simulation of model (2.1) persistent chemotherapy for <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x223.png" xlink:type="simple"/></inline-formula> and<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x223.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x224.png" xlink:type="simple"/></inline-formula>. (a) Simulation of uninfected CD4<sup>+</sup> T cells for<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x223.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x224.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x225.png" xlink:type="simple"/></inline-formula>; (b) Simulation of HI-virus infected CD4+ T cells for<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x223.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x224.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x225.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x226.png" xlink:type="simple"/></inline-formula>; (c) Simulation of pathogen infected CD4<sup>+</sup> T cells for<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x223.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x224.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x225.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x226.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x227.png" xlink:type="simple"/></inline-formula>; (d) Simulation of viral load in the blood plasma for<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x223.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x224.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x225.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x226.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x227.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x228.png" xlink:type="simple"/></inline-formula>; (e) Simulation of pathogen in the blood plasma for<inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x223.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x224.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x225.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x226.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x227.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x228.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x229.png" xlink:type="simple"/></inline-formula></title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/69198x222.png"/></fig><p>to near zero after 24 months; while from <xref ref-type="fig" rid="fig4">Figure 4</xref>(c), <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/69198x230.png" xlink:type="simple"/></inline-formula>which showed initial increase at the first month, decline thereafter to near zero in the 11 month of chemotherapy administration. From <xref ref-type="fig" rid="fig4">Figure 4</xref>(d) and <xref ref-type="fig" rid="fig4">Figure 4</xref>(e), the non-replications of infected T-cells invariably had de-transmuted into the decline and elimination of both viral load and parasitoid pathogen to near zero after 22 months and 9 months respectively.</p></sec><sec id="s4"><title>4. Conclusion</title><p>In this paper, nonlinear 5-Dimensional mathematical models had been formulated with which the compatibility of optimal control strategy for parameter estimation of dual infectivity (HI-virus and parasitoid-pathogen) was investigated. Using discretization technique, it was established that optimization control strategy were incompatible with the particular model, following the insignificant non-singularities of the model coefficients, which led to varying error derivatives. The study further explored predominant parameters to investigate the maximization of healthy blood plasma and the trend of the viruses, following coherent chemotherapy. Time limit for chemotherapy was established with which simulation was conducted. Analysis of results showed that restoration and increase of healthy blood plasma were achieved with the administration of chemotherapy from set point. Furthermore, with the distortion of viruses’ replication and de-transmutation of healthy blood plasma by viruses from the point of chemotherapy application, eradication of dual HI-virus and parasitoid-pathogen were achieved within the ambit of chemotherapy time validity. The study therefore suggested the extension of model in the evaluation of other related dual infectious diseases. Furthermore, a more improved 5-Dimensioanl model compatible with the application of optimal control strategy is thereof recommended.</p></sec><sec id="s5"><title>Acknowledgements</title><p>The authors (Bassey B. E, Lebedev, K. A), acknowledge with thanks, the support of the Department of Math and Computer Science; and Galina Govorova-Head of International Relation, Kuban State University, Krasnodar, Russia, for their immense contributions.</p></sec><sec id="s6"><title>Cite this paper</title><p>Bassey E. Bassey,Lebedev K. Andreyevich, (2016) On Analysis of Parameter Estimation Model for the Treatment of Pathogen-Induced HIV Infectivity. Open Access Library Journal,03,1-13. doi: 10.4236/oalib.1102603</p></sec><sec id="s7"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.69198-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Shirazian, M. and Farahi, M.H. (2010) Optimal Control Strategy for a Fully Determined HIV Model. Intelligent Control and Automation, 1, 15-19. http://dx.doi.org/10.4236/ica.2010.11002</mixed-citation></ref><ref id="scirp.69198-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Wei, X., Ghosh, S.K., Taylor, M.E., Johnson, V.A., Emini, E.A., Deutsch, P. and Lifson, J.D. (1995) Viral Dynamics in HIV-1 Infection. Nature, 273, 117-122. http://dx.doi.org/10.1038/373117a0</mixed-citation></ref><ref id="scirp.69198-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Nowak, M.A. and Bangham, C.R.M. (1996) Population Dynamics of Immune Responses to Persistent Viruses. Science, 272, 74-79. http://dx.doi.org/10.1126/science.272.5258.74</mixed-citation></ref><ref id="scirp.69198-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Xia, X. (2003) Estimation of HIV/AIDS Parameters. Automatica, 39, 1983-1988. http://dx.doi.org/10.1016/S0005-1098(03)00220-6</mixed-citation></ref><ref id="scirp.69198-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Xia, X. (2007) Modelling of HIV Infection: Vaccine Readiness, Drug Effectiveness and Therapeutical Failures. Journal of Process Control, 17, 253-260. http://dx.doi.org/10.1016/j.jprocont.2006.10.007</mixed-citation></ref><ref id="scirp.69198-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Badakhshan, K.P. and Kamyad, A.V. (2007) Numerical Solution of Nonlinear Optimal Control Problems Using Nonlinear Programming. Applied Mathematics and Computation, 187, 1511-1519. http://dx.doi.org/10.1016/j.amc.2006.09.074</mixed-citation></ref><ref id="scirp.69198-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Grégio, J.M., Caetano, M.A.L. and Yoneyama, T. (2009) State Estimation and Optimal Long Period Clinical Treatment of HIV Seropositive Patients. Anais da Academia Brasileira de Ciências, 81, 3-12. http://dx.doi.org/10.1590/S0001-37652009000100002</mixed-citation></ref><ref id="scirp.69198-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Wein, L.M., Zenios, S.A. and Nowak, M.A. (1997) Dynamic Multidrug Therapies for HIV: A Control Theoretic Approach. Journal of Theoretical Biology, 185, 15-29. http://dx.doi.org/10.1006/jtbi.1996.0253</mixed-citation></ref><ref id="scirp.69198-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Badakhshan, K.P., Kamyad, A.V. and Azemi, A. (2007) Using AVK Method to Solve Nonlinear Problems with Uncertain Parameters. Applied Mathematics and Computation, 189, 27-34. http://dx.doi.org/10.1016/j.amc.2006.11.172</mixed-citation></ref><ref id="scirp.69198-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ouattara, D.A. (2005) Mathematical Analysis of the HIV-1 Infection: Parameter Estimation, Therapies Effectiveness and Therapeutical Failures. Proceedings of the 2005 IEEE, Engineering in Medicine and Biology 27th Annual Conference, Shanghai, 1-4 September 2005, 821-824.</mixed-citation></ref><ref id="scirp.69198-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M. and Markowitz, M. (1995) Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection. Nature, 273, 123-126. http://dx.doi.org/10.1038/373123a0</mixed-citation></ref><ref id="scirp.69198-ref12"><label>12</label><mixed-citation publication-type="book" xlink:type="simple">Bassey, B.E. and Lebedev, K.A. (2015) On Mathematical Model of the Impact of Verimia Levels and Condom Use: Preventive Measures for the Spread of HIV/AIDS. Proceedings of XVIII-th International Scientific Conference “Modern Science: Actual Problems and Ways of Their Solution”, Lipetsk, 20 July 2015, Ed. by M. Y. Levin, Lipetsk: OOO Max Information Technology. 18, 5, 47-56. (In Russian)</mixed-citation></ref><ref id="scirp.69198-ref13"><label>13</label><mixed-citation publication-type="book" xlink:type="simple">Bassey, B.E. and Lebedev, K.A. (2015) On the Mathematical Modeling of the Impact of Numerical Stability of the Treatment of Vertical Transmitted HIV/AIDS Infections. Proceedings of XVI-th International Scientific Conference “Scientific Potential of Contemporary Russia”, Lipetsk, 10 August 2015, Ed. by M. Y. Levin, Lipetsk: OOO Max Information Technology. 16, 5, 7-19. (In Russian)</mixed-citation></ref><ref id="scirp.69198-ref14"><label>14</label><mixed-citation publication-type="book" xlink:type="simple">Bassey, B.E. and Lebedev, K.A. (2015) On Global Convergence and Impact of Multistageand Pad&amp;#232; Techniques for Iterative Methods in Nonlinear HIV/AIDS Preventive Chain Model. Proceedings of the XIX-th International Scientific Conference “Modern Science: Current Problems and Solutions”, Lipetsk, 14 September 2015, Ed. By M. Levin, Lipetsk: LLC Maximal Information Technologies. 19, 6, 17-27. (In Russian)</mixed-citation></ref><ref id="scirp.69198-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wikipedia (2015) The Free Encyclopedia, Immune System. https://en.wikipedia.org/wiki/Immune_system/</mixed-citation></ref><ref id="scirp.69198-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Pattman, R., Snow, M., Handy, P., Sankar, K.N. and Elawad, B. (2005) Oxford Handbook of Genitourinary Medicine, HIV and AIDS. Oxford University Press, USA.</mixed-citation></ref><ref id="scirp.69198-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Fister, K.R. and Lenhart, S. (1998) Optimizing Chemotherapy in an HIV Model. Journal of Differential Equations, 1998, 1-12.</mixed-citation></ref><ref id="scirp.69198-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Joshi, H.R. (2002) Optimal Control of an HIV Immunology Model. Optimal Control Applications and Methods, 23, 199-213. http://dx.doi.org/10.1002/oca.710</mixed-citation></ref><ref id="scirp.69198-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kirschner, D. and Webb, G.F. (1998) Immunotherapy of HIV-1 Infection. Journal of Biological Systems, 6, 71-83. http://dx.doi.org/10.1142/S0218339098000091</mixed-citation></ref><ref id="scirp.69198-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Butler, S., Kirschner, D. and Lenhart, S. (2016) Optimal Control of Chemotherapy Affecting the Infectivity of HIV. http://www.nacad.ufrj.br/~amit/opt_infect_HIV_kirsch.pdf</mixed-citation></ref></ref-list></back></article>